Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16877393 | 0.88 | CYP2C9 (0.42) | ALDH1A1CYP2D6CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL30128154 | 0.86 | SLC6A2 (0.34) | TSHR | |
| SCHEMBL16877915 | 0.86 | SLC6A2 (0.34) | TSHR | |
| SCHEMBL16877918 | 0.86 | ALDH1A1 (0.31) | ALDH1A1CYP2D6CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL30127990 | 0.86 | SLC6A2 (0.34) | TSHR | |
| SCHEMBL165850 | 0.85 | MEN1 (0.35) | CYP2C9MEN1KMT2AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL3412745 | 0.83 | MEN1 (0.33) | CYP2C9MEN1KMT2AKDM4EGAA | |
| SCHEMBL16877360 | 0.83 | MEN1 (0.46) | CYP2C9MEN1KMT2AKDM4EGAA | |
| SCHEMBL16503412 | 0.82 | — | — | |
| SCHEMBL15680849 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083258-A1 | KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | claimed |
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | claimed |
| EP-2528910-B1 | 5-Alkynyl pyrimidines ahd their use as kinase inhibitors. | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8618111-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| EP-2528910-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| WO-2011092197-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | claimed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20240391877-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO.,LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| EP-4410776-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Wuhan Createrna Science and Technology Co.,Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024083258-A1 | KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| WO-2023051793-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2023-04-06 | — | — | WO | disclosed |
| US-20120028952-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092197-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092198-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | ALDH1A1 1452/4885CYP2D6 422/4885CYP3A4 1179/4885 |
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | ALDH1A1 79/4885CYP2D6 298/4885CYP3A4 1080/4885 |
| US-20120028952-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | ALDH1A1 46/4885CYP2D6 220/4885CYP3A4 1251/4885 |
| US-20240391877-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CFD, CFH, C9 | ALDH1A1 2758/4885CYP2D6 410/4885CYP3A4 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.